Author Archives: William Looney

Engage, But Gently: More Top Line Thoughts on 2014

More Top Line Thoughts on 2014:  Engage, but Gently Two weeks in and the New Year already seems old.  Yet members of our Pharm Exec Editorial Advisory Board are still eager to share their top of line predictions on trends that will shape the industry’s business and reputational assets – forward and backward – over […]
Posted in Op-Ed, Strategy | Tagged , , , , , , , | Leave a comment

The Pulsing Pharmaceutical: Bioelectronics

GSK Lights a Spark around Bioelectronics Dominating the frontier of medicines discovery is a simple, endlessly challenging question: if not a drug, then what?  Industry science has evolved from the chemical roots of the small molecule to the biologics synthesized from living organisms, but the delivery mechanism – pill or injectable – is basically the […]
Posted in Global, R&D, Technology | Tagged , , , , | 1 Comment

Fred Hassan: More Musings on the Biopharma Learning Curve

Hindsight can be a great teacher – but only if you have the self-awareness needed to adapt those learnings to the next business challenge, whose rough edges are by definition almost always “non-recurring.” In other words, because the circumstances of any setback are unique, the astute manager knows that recovery depends on recognizing that the […]
Posted in healthcare, leadership, People, R&D, Sales, Strategy | Tagged , , , , , | 2 Comments

Russian Innovation: A Higher Mark

The pursuit of excellence in biopharmaceutical innovation in Russia has never had a sponsor—until now. Prix Galien International, a global network of Nobel laureates in medicines, established its 18th country beachhead in Moscow earlier this year, culminating in a historic first: an October 24 awards dinner to recognize the best in new drug research as […]
Posted in E-Media, Events, R&D, Strategy | Tagged , , , , , , , , | Leave a comment

Nano Tech: Big Stakes in Small Things

Nano Tech: Big Stakes in Small Things New and emerging technologies are noteworthy not simply for the excellent science behind them but also for the way they expose those raw edges of the industry’s business model. In biopharma today, disruptive changes to the model are being driven by two forces. The first is advances in […]
Posted in Events, Regulatory, Technology | Tagged , , | Leave a comment
  • Categories

  • Meta